Replies to post #401742 on NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

And still no true TLD (the comparison between the 2 main trial arms).

This is not the true TLD. It's the old TLD.

You know there will be an issue with pseudo-progression in the primary endpoint. The question is, did the treatment work so well (because that is what the psPD was indicative of) that the primary endpoint couldn't be proven as a result?

If that secondary fourth end point is not stat sig, then that will be the reason. IMO, stuff like that is much more easily explained in a comprehensive peer-reviewed journal than in a company press release.

[GinGinGin]

and the subgroup analysis they are hyping is what is called exploratory

I disagree. Please read the "Treatment Arms vs. Subgroups" section at https://www.cvmresearch.com/p/cel-sci-cvm-fdas-recent-subgroup

Following section reasons about the pre-selection method. It is a bit of a gamble. What really puts multikine in a strong position is the outstanding safety profile - you can essentially administer it to everybody without a worry.

[flipper44]

NEJM basically states, one reason for peer reviewed published articles is so that the results of a study are not inappropriately or unwittingly hyped.